WASHINGTON (dpa-AFX) - Molecular diagnostic company Myriad Genetics Inc. (MYGN) Tuesday reported third-quarter net income of $29.6 million or $0.34 per share, compared to $28 million or $0.31 per share last year.
Analysts polled by Thomson Reuters expected earnings of $0.32 per share for the quarter. Analysts' estimates typically exclude special items.
Revenue for the quarter rose 27% to $130 million from $102.4 million a year ago. Analysts expected revenue of $119.34 million.
Looking ahead, the company raised its expectations for fiscal year 2012. Total revenue is now expected to be $492 million to $496 million, compared to the company's prior guidance of $445 million to $465 million. The company now expects full year 2012 earnings of $1.29 to $1.31 per share, up from the original guidance of $1.20 to $1.25 per share.
Analysts currently expect earnings of $1.26 per share and revenue of $474.57 million for the full year 2012.
Copyright RTT News/dpa-AFX
© 2012 AFX News
